Matthew Randesi1, Wim van den Brink2,3, Orna Levran1, Vadim Yuferov1, Peter Blanken2,4, Jan M van Ree2,5, Jurg Ott6, Mary Jeanne Kreek1. 1. Laboratory of the Biology of Addictive Diseases, The Rockefeller University, 1230 York Ave, New York, NY 10065, USA. 2. Central Committee on the Treatment of Heroin Addicts (CCBH), Universiteitsweg 100, 3584 CG Utrecht, The Netherlands. 3. Amsterdam Institute for Addiction Research, Department of Psychiatry, Academic Medical Center, University of Amsterdam, PO Box 22660, 1100 DD Amsterdam, The Netherlands. 4. Parnassia Addiction Research Centre (PARC, Brijder Addiction Treatment) PO Box 53002, 2505 AA The Hague, The Netherlands. 5. Brain Center Rudolf Magnus, University Medical Center Utrecht, Utrecht University, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands. 6. Laboratory of Statistical Genetics, The Rockefeller University, 1230 York Ave, New York, NY 10065, USA.
Abstract
AIM: To determine whether specific dopaminergic system gene variants are associated with opioid dependence. PATIENTS & METHODS: Subjects included 153 healthy controls, 163 opioid exposed, but not dependent and 281 opioid dependent. Genotypes of 90 variants in 13 genes were examined. RESULTS: The most significant results were obtained for DA β-hydroxylase variants, rs2073837 and rs1611131, which were associated with protection from addiction (q = 0.0172, 0.0415, respectively) and the functional TH variant, rs2070762, was associated with more risk (q = 0.0387). The three variants also showed a combined effect that remained significant after correction for multiple testing (pfinal = 0.0039). CONCLUSION: These data offer support that dopaminergic gene variants have a role in opioid dependence and warrant further study.
AIM: To determine whether specific dopaminergic system gene variants are associated with opioid dependence. PATIENTS & METHODS: Subjects included 153 healthy controls, 163 opioid exposed, but not dependent and 281 opioid dependent. Genotypes of 90 variants in 13 genes were examined. RESULTS: The most significant results were obtained for DA β-hydroxylase variants, rs2073837 and rs1611131, which were associated with protection from addiction (q = 0.0172, 0.0415, respectively) and the functional TH variant, rs2070762, was associated with more risk (q = 0.0387). The three variants also showed a combined effect that remained significant after correction for multiple testing (pfinal = 0.0039). CONCLUSION: These data offer support that dopaminergic gene variants have a role in opioid dependence and warrant further study.
Authors: Orna Levran; Matthew Randesi; Joel Correa da Rosa; Jurg Ott; John Rotrosen; Miriam Adelson; Mary Jeanne Kreek Journal: Ann Hum Genet Date: 2015-02-27 Impact factor: 1.670
Authors: Peter Blanken; Wim van den Brink; Vincent M Hendriks; Ineke A Huijsman; Marjolein G Klous; Elisabeth J Rook; Jennifer S Wakelin; Cas Barendrecht; Jos H Beijnen; Jan M van Ree Journal: Eur Neuropsychopharmacol Date: 2010-04 Impact factor: 4.600
Authors: Toni-Kim Clarke; Amy R D Weiss; Thomas N Ferarro; Kyle M Kampman; Charles A Dackis; Helen M Pettinati; Charles P O'brien; David W Oslin; Falk W Lohoff; Wade H Berrettini Journal: Ann Hum Genet Date: 2013-11-25 Impact factor: 1.670
Authors: Joseph F Cubells; Xiangqing Sun; Wenbiao Li; Robert W Bonsall; John A McGrath; Dimitri Avramopoulos; Virginia K Lasseter; Paula S Wolyniec; Yi-Lang Tang; Kristina Mercer; Ann E Pulver; Robert C Elston Journal: Hum Genet Date: 2011-04-21 Impact factor: 4.132
Authors: Francesca Ducci; Alec Roy; Pei-Hong Shen; Qiaoping Yuan; Nicole P Yuan; Colin A Hodgkinson; Lynn R Goldman; David Goldman Journal: Am J Psychiatry Date: 2009-07-15 Impact factor: 18.112
Authors: Meredith S Shiels; Han Yao Huang; Sandra C Hoffman; Yin Yao Shugart; Judy Hoffman Bolton; Elizabeth A Platz; Kathy J Helzlsouer; Anthony J Alberg Journal: Prev Med Date: 2008-04-01 Impact factor: 4.018
Authors: O Levran; D Londono; K O'Hara; D A Nielsen; E Peles; J Rotrosen; P Casadonte; S Linzy; M Randesi; J Ott; M Adelson; M J Kreek Journal: Genes Brain Behav Date: 2008-06-02 Impact factor: 3.449
Authors: Adam M Leventhal; Wonho Lee; Andrew W Bergen; Gary E Swan; Rachel F Tyndale; Caryn Lerman; David V Conti Journal: Drug Alcohol Depend Date: 2014-03-05 Impact factor: 4.492
Authors: Vadim Yuferov; Matthew Randesi; Eduardo R Butelman; Wim van den Brink; Peter Blanken; Jan M van Ree; Jürg Ott; Mary Jeanne Kreek Journal: Neurosci Lett Date: 2019-03-29 Impact factor: 3.046
Authors: Matthew Randesi; Wim van den Brink; Orna Levran; Peter Blanken; Jan M van Ree; Jurg Ott; Mary Jeanne Kreek Journal: Pharmacogenomics Date: 2019-04-15 Impact factor: 2.533
Authors: Mitchell R Knisely; Yvette P Conley; Betty Smoot; Steven M Paul; Jon D Levine; Christine Miaskowski Journal: J Pain Date: 2019-03-21 Impact factor: 5.820
Authors: Matthew Randesi; Orna Levran; Wim van den Brink; Peter Blanken; Jan M van Ree; Jurg Ott; Mary J Kreek Journal: Pharmacogenomics Date: 2020-08-06 Impact factor: 2.533
Authors: Vadim Yuferov; Eduardo R Butelman; Matthew Randesi; Wim van den Brink; Peter Blanken; Jan M van Ree; Mary Jeanne Kreek Journal: Neuropsychiatr Dis Treat Date: 2021-02-25 Impact factor: 2.570
Authors: K Blum; D Baron; M Hauser; S Henriksen; P K Thanos; C Black; D Siwicki; E J Modestino; B W Downs; S Badgaiyan; T A Simpatico; B Boyett; R D Badgaiyan Journal: J Syst Integr Neurosci Date: 2019-10-31